Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy resultsMichael Wang, Simon Rule, Rebecca Auer et al.|Blood|2015Cited by 408
Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 StudyMichael Wang, Kristie A. Blum, Simon Rule et al.|Blood|2014Cited by 16